Korakot NGANVONGPANIT, Burin BOONSRI, Thatdanai SRIPRATAK, Patsanan MARKMEE, Prachya KONGTAWELERT

Clinical study on the effects of diacerein and diacerein combined with chondroitin sulfate on canine hip osteoarthritis

Bu çalışma Diacerein (DAR) ve Kondroitin Sülfat (CS) Eklenmiş Diacerein ’in tedavi amaçlı olarak Canin Kalça Osteoartritisinde (OA) 6 aylık klinik denemedeki etkisini değerlendirmeyi amaçlamaktadır. Çalışmada yaşları 59.43±17.05 ay ve kiloları 17.63±5.19 kg arasında değişen 27 erkek ve 25 dişi sahipli kopek kullanıldı. Köpekler rastgele olarak 5 gruba ayrıldı; DAR50 (günlük 50 mg DAR uygulanan); DAR100 (günlük 100 mg DAR); DAR50/CS (günlük 50 mg DAR + 525 mg CS); DAR100/CS (günlük 100 mg DAR + 525 mg CS) ve CS (günlük 525 mg CS). Köpekler tedavinin başlangıcından itibaren aylık olarak 6 ay boyunca yeniden muayene edildi. Protokol değerlendirmesi klinik skoru ve radyografik bulguları içerdi. Kan örnekleri üç defa (tedavi öncesi, tedavinin 3. ve 6. aylarında) serum biyomarkırı CS-WF6’nın değerlendirilmesi amacıyla toplandı. DAR ile tedavi edilen köpeklerde topallık, eklem hareketliliği, dokunmaya karşı acı, ağırlık taşıma ve genel olarak sırasıyla 3, 6, 5, 4 ve 4 aylarda klinik skorda tedavinin başlangıcından sonra istatistiksel olarak önemli derecede iyileşmeler gösterdi. İshal ve koyu renkli idrar yan etki olarak DAR alan tüm gruplarda gözlendi. Üçüncü aydan sonra CS grubunda serum CS-WF6 düzeyi önemli ölçüde yükselirken (P

Diacerein ve kondroitin sülfat eklenmiş diacerein’in köpek kalça osteoartritisindeki etkileri üzerine klinik bir çalışma

This study aimed to evaluate the effects of diacerein (DAR) and DAR combined with chondroitin sulfate (CS) for treatment of canine hip osteoarthritis (OA) in a 6-month clinical trial. Client-owned dogs included in the study consisted of 27 males and 25 females, aged 59.43±17.05 months old and weighing 17.63±5.19 kg. The dogs were randomly divided into five groups: DAR50 (administration of DAR 50 mg daily); DAR100 (DAR 100 mg daily); DAR50/CS (DAR 50 mg + CS 525 mg daily); DAR100/CS (DAR 100 mg + CS 525 mg daily); and CS (CS 525 mg daily). Dogs were re-examined monthly for 6 months after initiation of treatment. The assessment protocol included clinical scores and radiographic findings. Blood samples were collected three times (pre-treatment, and after 3 and 6 months) for evaluation of the serum biomarker, CS-WF6. Dogs treated with DAR showed statistically significant improvements (P<0.05) in lameness, joint mobility, pain on palpation, weight-bearing, and overall clinical score at 3, 6, 5, 4, and 4 months, respectively, after the start of treatment. Side effects, including diarrhea and dark-colored urine, were found in all groups receiving DAR. After the 3rd month, the level of serum CS-WF6 in the CS group was significantly elevated (P<0.05), while the other four groups showed a significant decrease (P<0.05). The results showed that DAR 50 or 100 mg had a similarly positive therapeutic effect on dogs with osteoarthritis. The use of DAR alone or in combination with CS resulted in decreased degradation of OA cartilage.

___

1. Rintelen B, Neumann K, Leeb BF: A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med, 166, 1899-1906, 2006.
2. Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, Reichenbach S, Trelle S: Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: Network meta-analysis. BMJ, 341, c4675, 2010.
3. Bruyère O, Burlet N, Delmas PD, Rizzoli R, Cooper C, Reginster JY: Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord, 9, 165, 2008.
4. Nakasone Y, Watabe K, Watanabe K, Tomonaga A, Nagaoka I, Yamamoto T, Yamaguchi H: Effect of a glucosamine-based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: A pilot study. Exp Ther Med, 2, 893-899, 2011.
5. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, Bingham CO, Reda DJ, Moskowitz RW, Williams HJ, Clegg DO: Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis, 69, 1459-1464, 2010.
6. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H: Role of proinflammatory cytokines in the pathophysiology of osteo- arthritis. Nat Rev Rheumatol, 7, 33-42, 2011.
7. Daheshia M, Yao JQ: The interleukin 1β pathway in the pathogenesis of osteoarthritis. J Rheumatol, 35, 2306-2312, 2008.
8. Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J: Diacerhein and rhein reduce the interleukin 1 beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol, 25, 2417-2424, 1998.
9. Martel-Pelletier J, Pelletier JP: Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis, 2, 95-104, 2010.
10. Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP: In vitro effects of diacerhein and rhein on interleukin-1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol, 25, 753-762, 1998.
11. Boileau C, Tat SK, Pelletier JP, Cheng S, Martel-Pelletier J: Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: A possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther, 10, R71, 2008.
12. Pelletier JP, Mineau F, Boileau C, Martel-Pelletier J: Diacerein reduces the level of cartilage chondrocyte DNA fragmentation and death in experimental dog osteoarthritic cartilage at the same time that it inhibits caspase-3 and inducible nitric oxide synthase. Clin Exp Rheumatol, 21, 171-177, 2003.
13. Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, Wigler I, Rosner IA, Beaulieu AD: Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum, 43, 2339-2348, 2000.
14. Nicolas P, Tod M, Padoin C, Petitjean O: Clinical pharmacokinetics of diacerein. Clin Pharmacokinet, 35, 347-359, 1998.
15. Magnard O, Louchahi K, Tod M, Petitjean O, Molinier P, Berdah L, Perret G: Pharmacokinetics of diacerein in patients with liver cirrhosis. Biopharm Drug Dispos, 14, 401-408, 1993.
16. Debord P, Louchahi K, Tod M, Molinier P, Berdah L, Petitjean O: Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. Eur J Drug Metab Pharmacokinet, 19, 13-19, 1994.
17. Dougados M, Nguyen M, Berdah L, Maziéres B, Vignon E, Lequesne M, ECHODIAH Investigators Study Group: Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum, 44, 2539-2547, 2001.
18. Brandt KD, Smith G, Kang SY, Myers S, O’Connor B, Albrecht M: Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cartilage, 5, 438-449, 1997.
19. Fidelix TS, Soares BG, Trevisani VF: Diacerein for osteoarthritis. Cochrane Database Syst Rev, 25, CD005117, 2006.
20. Smith GNJ, Myers SL, Brandt KD, Mickler EA, Albrecht ME: Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis and Rheumatism, 42, 545–554, 1999.
21. Nganvongpanit K, Pothacharoen P, Suwankong N, Ong-Chai S, Kongtawelert P: The effect of doxycycline on canine hip osteoarthritis: Design of a 6-months clinical trial. J Vet Sci, 10, 239-247, 2009.
22. McCarthy G, O’Donovan J, Jones B, McAllister H, Seed M, Mooney C: Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Vet J, 174, 54-61, 2007.
23. Takahashi M, Naito K, Abe M, Sawada T, Nagano A: Relationship between radiographic grading of osteoarthritis and the biochemical markers for arthritis in knee osteoarthritis. Arthritis Res Ther, 6, R208-212, 2004.
24. Nganvongpanit K, Itthiarbha A, Ong-Chai S, Kongtawelert P: Evaluation of serum chondroitin sulfate and hyaluronan: Biomarkers for osteoarthritis in canine hip dysplasia. J Vet Sci, 9, 317-325, 2008.
25. Nganvongpanit K, Pothacharoen P, Chaochird P, Klunklin K, Warrit K, Settakorn J, Pattamapaspong N, Luevitoonvechkij S, Arpornchayanon O, Kongtawelert P, Pruksakorn D: Prospective evaluation of serum biomarker levels and cartilage repair by autologous chondrocyte transplantation and subchondral drilling in a canine model. Arthritis Res Ther, 11, R78, 2009.
26. Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S (Thai Study Group): The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: A randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage, 15, 605-614, 2007.
27. Pothacharoen P, Teekachunhatean S, Louthrenoo W, Yingsung W, Ong-Chai S, Hardingham T, Kongtawelert P: Raised chondroitin sulfate epitopes and hyaluronan in serum from rheumatoid arthritis and osteoarthritis patients. Osteoarthritis Cartilage, 14, 299-301, 2006.